Longeveron Inc. (LGVN) Stock Score, Valuation & Financial Research
Longeveron Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for LGVN
Longeveron Inc. currently has a Wall Street Score of 21/100. The stored market price is $7.33. Its financial score is 8/100. Its valuation score is 0/100. The latest WSS change is -2.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What Longeveron Inc. does
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florid
LGVN financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $7.33
- Market capitalization:
- $22.3M
- Revenue:
- $1.2M
- Net income:
- $-23.5M
- Free cash flow:
- $-18.9M
- Cash:
- $10.1M
- Total debt:
- $581K
- EPS:
- -10.10
- Financial score:
- 8/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-18.9M, showing cash burn in the current stored period.
- The balance sheet shows $10.1M of cash versus $581K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -2.0 points: LGVN decreased 2 points because Asset declined by 18.8 points, Buffett declined by 3.2 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 8/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research LGVN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.